Wondfo Biotech Participates in Atlas Genetics' $35 Million Round

Guangzhou Wondfo Biotech participated in a $35 million Series D funding of Atlas Genetics of the UK. Both companies make molecular diagnostic tests. The announcement did not include any hint that Wondfo would acquire China rights to Atlas's tests or platform technology, though an agreement may follow later. Wondfo is an established Chinese IVD company, with a market capitalization of $1.5 billion. It makes a broad range of diagnostic assays including several POC tests. More details.... Stock Symbol: (SHZ: 300482) Share this with colleagues: // //